Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paediatric Hepatic International Tumour Trial
NCT03017326Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Aug 2017
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised trial of cisplatin, doxorubicin, carboplatin, fluorouracil, vincristine and 5 more in hepatoblastoma and hepatocellular carcinoma (HCC) (6 arms), sponsored by University of Birmingham. Primary endpoints: Event-Free Survival at 6 years and Objective Response Rate at 63 days. Started Aug 2017; status: active, not recruiting.
02
Drugs
cisplatindoxorubicincarboplatinfluorouracilvincristine
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03017326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017326.